<DOC>
	<DOCNO>NCT00365937</DOCNO>
	<brief_summary>Open-label single center study . Patients divide four group 7 . Group 1 : 8 melanoma-specific peptide saline ; Group 2 : mix peptide + Montanide ISA51 ; Group 3 : mix peptide + IMP321 500 µg ; Group 4 : mix peptide + IMP321 500 µg + Montanide ISA51 . These vaccine administer every 3 week 5 occasion intradermal superficial subcutaneous injection .</brief_summary>
	<brief_title>Immunization Disease-Free Melanoma Patients With Different HLA-A2 Peptides</brief_title>
	<detailed_description>Open-label single center study . Patients divide four group 7 . The patient enter sequentially time present clinic , randomize one four group . The first group patient receive dose 300 µg MAGE-1.A2 , MAGE-3.A2 , MAGE-4.A2 , MAGE-10.A2 , MAGE-C2.A2 , NA17.A2 , Tyrosinase.A2 NY-ESO-1.A2 peptide without adjuvant . The peptide mix together administer intradermal superficial subcutaneous injection two site every three week 5 occasion ( 3 month ) . The second group patient receive 5 occasion vaccine contain 8 peptide mixed together emulsify 1 ml Montanide ISA51 . This vaccine also administer intradermal subcutaneous injection every three week . The third cohort patient receive 3 weeks-interval 5 occasion mix 8 peptide 500 µg IMP321 . These two injection do site , first adjuvant IMP321 peptide . The last seven patient receive vaccine mix peptide emulsify Montanide ISA 51 VG IMP321 inject procedure cohort 3 . These vaccine administrate every 3 week 5 occasion intradermal superficial subcutaneous injection . Blood sample obtain buffy-coat week 1 16 . PBL collect baseline ( day 1 ) week 16 test determine whether specific CTL response , define 10-times increase CTL frequency , occur . For patient anti-vaccine lymphocyte response , 100 ml blood collect every three month order monitor immune response . If decrease CTL frequency factor 10 observe , patient revaccinated three time three week interval peptide ( ) develop immune response mixed adjuvant already receive . The disease status assess study entry thereafter every 3 month one year . At time , relapse result withdrawal patient trial .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Adjuvants , Immunologic</mesh_term>
	<mesh_term>Freund 's Adjuvant</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Histologically proven cutaneous melanoma . Patient 's melanoma must one follow AJCC stage : primary tumor : T3bT4 , N0 , M0 . regional lymph node metastasis and/or intransit metastasis , distant metastasis ( T , N1N3 , M0 ) remove . Any distant metastasis remove ( M1 ) HLAA2 positive . Patients previous regional metastatic disease must one resect lesion analyze RTPCR determine expression gene MAGE1 , MAGE3 , MAGE4 , MAGE10 , MAGEC2 , NA17 , Tyrosinase NYESO1 . However , expression gene tumor require enter study . Absence detectable melanoma lesion . WHO/ECOG performance status 1 less ( Karnofsky scale ≥ 70 % ) . The following laboratory result : Hemoglobin ≥ 10 g/dl ; Neutrophils ≥ 1,500/µl ; Lymphocytes ≥ 700/µl ; Platelets ≥ 100,000/µl ; Serum creatinin ≤ 2.0 mg/dl ; Serum bilirubin ≤ 2.0 mg/dl ; LDH within normal institutional limit . Age &gt; 18 year . Able give write informed consent . Clinically significant heart disease ( NYHA Class III IV ) . Other serious illness , e.g . serious infection require antibiotic , bleed disorder , second active malignancy , except basal cell carcinoma situ carcinoma uterine cervix . Active immunodeficiency disease autoimmune disease . Positive serology HIV ( human immunodeficiency virus ) HCV ( hepatitis C virus ) . Serum hepatitis B antigen ( HBsAg ) must negative . More one line previous chemotherapy , immunotherapy melanoma . Previous vaccination one antigen present vaccine . Treatment steroid major immunosuppressive drug within 4 week study entry . Topical inhalational steroid permit . Participation clinical trial involve another investigational agent within 4 week prior enrollment . Pregnancy lactation . Women childbearing potential use medically acceptable mean contraception . Psychiatric addictive disorder may compromise ability give informed consent . Lack availability patient immunological clinical followup assessment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2010</verification_date>
	<keyword>immunotherapy</keyword>
	<keyword>adjuvant</keyword>
	<keyword>IMP321</keyword>
	<keyword>Montanide ISA51 VG</keyword>
	<keyword>tumor-specific peptide</keyword>
</DOC>